Gastroenterology Pipeline Update: New Treatments for Ulcerative Colitis, Crohn's Disease

When treating ulcerative colitis (UC) and Crohn’s disease (CD), health care providers have several options at their fingertips.

“Since the approval of Remicade [infliximab] in 2005, there have been 7 initial products approved for moderate to severe UC, and several agents are in phase 3 trials for CD,” said Courtney Queen, PharmD, CSP, of the University of Kentucky Specialty Pharmacy and Infusion Services in Lexington, Kentucky, during her presentation on the specialty pharmacy pipeline at the 2023 American Society of Health-System Pharmacists (ASHP) Summer Meetings and Exhibition held June 10 to 14 in Baltimore, Maryland.¹

Medications that are indicated for the treatment of one of these conditions, Queen explained, frequently seek indication to treat the other. Read on for highlights of the gastroenterology drug pipeline.

Reference

1. Rim M, Queen C, Huffmyer M. Specialty pharmacy pipeline updates II: Emerging therapies for complex conditions. Presented at: American Society of Health-System Pharmacists Summer Meetings and Exhibition; June 10-14, 2023; Baltimore, MD.